An Open Label Trial of BI 765063 in Combination With BI 754091 (Ezabenlimab) Alone or With BI 836880, Chemotherapy, or Cetuximab, in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) or Hepatocellular Carcinoma (HCC) (BI1443-0002)
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
DR VOON PEI JYE
voonpj@yahoo.com
CONTACT
General line: 082 – 276666
CRC: 082-276820 (Tel)
082-276823 (Fax)
Tiong Lee Len, Admin Manager
leelen.crc@gmail.com (Email)
Facebook
Sultan Ismail Hospital, Johor Bahru
PRINCIPAL INVESTIGATOR
DR LIM CHUN SEN
chunsen1@hotmail.com
CONTACT
General line: 07 – 356 5000
CRC: 07 – 356 5000 ext: 2408
Dr Munirah Admin Manager
drmunirah@hsi.gov.my (Email)
University of Malaya Medical Centre (UMMC)
PRINCIPAL INVESTIGATOR
Dr Ho Gwo Fuang
fuang@ummc.edu.my
CONTACT
SC: Kimee 03-79492120 (Research Room)
National Cancer Institute (IKN)
PRINCIPAL INVESTIGATOR
DR SUHANA BINTI YUSAK
suhanayusak@gmail.com
CONTACT
General line : 03 – 8892 5555
CRC: 03 – 8892 5555 Ext 5418 (Tel)
03- 8892 5622 (Fax)
A Study of Pembrolizumab (MK-3475) Plus Platinum and Gemcitabine as First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PIPER)
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
National Cancer Institute (IKN)
PRINCIPAL INVESTIGATOR
Dr Wong Yoke Fui
dryfwongnci.gov.my
CONTACT
SC: Abdul Hadi Hisham
abdul.hadi@clinicalresearch.my
Hospital Kuala Lumpur (HKL)
PRINCIPAL INVESTIGATOR
Dr Ibtisam Muhamad Nor
CONTACT
SC: Amirah binti Mohamed Tahir
amirah@clinicalresearch.my
Pulau Pinang Hospital
PRINCIPAL INVESTIGATOR
FONG CHIN HENG
CONTACT
SC: Nur Adilah Abdul Aziz
General line: ’04-2225 333
CRC: 042225 767 / 2225 762 / 2225 766 / 2225 586
Dr. Yoon Chee Kin, Ketua Jabatan
dryoonck@moh.gov.my (email)
Sister Zarina Bt Che Umar
Admin Manager zarinacu@gmail.com (Email)
University of Malaya Medical Centre (UMMC)
PRINCIPAL INVESTIGATOR
WAN ZAMNIAH WAN ISHAK
CONTACT
SC: Suganiya
Contact no: 03-79492120
Protocol title: A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (ORIGAMI-4)
University of Malaya Medical Centre (UMMC)
PRINCIPAL INVESTIGATOR
Dr David Lee Dai Wee
CONTACT
SC: Toh Yok Yong (03-79492120)